DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit

Core Insights - DBV Technologies, a late-stage biopharmaceutical company, will participate in the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11-12, 2026, with CEO Daniel Tassé scheduled to present on February 12 at 2:30 PM ET [1] Company Overview - DBV Technologies is focused on developing treatment options for food allergies and other immunologic conditions, utilizing its proprietary VIASKIN® patch technology [3] - The company aims to address food allergies through epicutaneous immunotherapy (EPIT), which introduces microgram amounts of biologically active compounds to the immune system via intact skin [3] - DBV's food allergy programs include ongoing clinical trials of VIASKIN® Peanut for peanut allergic toddlers (1-3 years) and children (4-7 years) [3] Operations and Trading - DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ [4] - The company's ordinary shares are traded on segment B of Euronext Paris and its American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market [4]